Dr. Suchita Pakkala, MD

Dr. Pakkala practices at Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University.

Dr. Pakkala's NPI, 1205013794, was assigned on January 27, 2008. Dr. Pakkala graduated from University of Tennessee, Hsc, College of Medicine in 2004. Dr. Pakkala holds Georgia license 059580.

Dr. Pakkala's primary practice is Emory University Hospital Midtown, at 550 Peachtree Street, NE, Atlanta, GA 30308 in Fulton County. The practice phone is (404) 686-2450.

Dr. Pakkala's primary practice is Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University. Dr. Pakkala is also affiliated with Emory University Hospital. The medical group on file is Emory Clinic. Dmand AI also links Dr. Pakkala to 3 more hospitals, 2 group practices and clinics, 1 clinical lab and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pakkala practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Pakkala's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Pakkala is licensed in Georgia.

CMS data shows 208 Medicare services from Dr. Pakkala across 6 procedure codes in 2024, for 76 Medicare patients. Medicare paid $11,712 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 76 Medicare patients who saw Dr. Pakkala in 2024. The largest group is 65 to 74, with 41 patients. 75% of them have cancer, and 75% have high blood pressure. 16% are also on Medicaid. Their average risk score is 1.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pakkala's median patient age at 70, with 89% women.

In 2024, Dr. Pakkala wrote 799 Medicare Part D claims for 198 patients. 81% of them were for generic drugs. CMS names the drug for 634 of them, across 17 drugs with 11 or more claims each, at $1,611,200 in total drug cost. In 2023, CMS named 805 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Pakkala for performance year 2024, reported through an alternative payment model (APM). Dr. Pakkala accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Pakkala as offering telehealth.

Dmand AI links 19 papers to Dr. Pakkala, published from 2011 to 2022. 2020 was the busiest year, with 3. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Pakkala has published most often in Clin Lung Cancer. Dr. Pakkala's most frequent co-authors are Suresh Sakkarai Ramalingam, MD, Fadlo R. Khuri, MD and Conor Ernst Steuer, MD.

Dmand AI links Dr. Pakkala to 8 clinical trials, 2 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Adenocarcinoma of Lung. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 28 general payments to Dr. Pakkala from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 63% of the total. Novartis Pharmaceuticals Corporation paid the most, $7,538.

Dr. Pakkala graduated from University of Tennessee, Hsc, College of Medicine in 2004.